在患有严重COVID-19的老年人中显著降低了陈诺德氧胆酸和甘基诺德氧胆酸
Shiyang Liu1,2, Wen Xu2, Bo Tu2
1Chinese People's Liberation Army (PLA) Medical School, Beijing 100853, China.
降低初级胆汁酸水平,氧化胆汁酸 (CDCA) 和糖氧化胆汁酸 (GCDCA),与老年患者的严重COVID-19有关. 这些胆汁酸可以作为严重的SARS-CoV-2感染的生物标志物和治疗点.
科学领域:
- * 代谢学和免疫学
- * 老年医学和传染病
背景情况:
- *老年COVID-19患者面临严重结果和细胞因子风暴的风险增加.
- * 在这个人口群体中,严重的SARS-CoV-2感染的特定生物标志物尚未确定.
- * 在严重的COVID-19中,主要胆酸代谢变化仍然在很大程度上未被探索.
研究的目的:
- * 为了研究严重COVID-19的老年患者的初级胆酸代谢变化.
- * 确定疾病严重程度和进展的潜在生物标志物.
- * 探索特定胆酸及其受体的抗炎作用.
主要方法:
- *老年COVID-19患者 (n=31) 的非向代谢量,其次是向代谢量.
- * 疾病进展的患者 (n=16) 与没有疾病进展的患者 (n=48) 的比较.
- *体外实验评估胆汁酸 (CDCA,GCDCA) 和受体 (FXR,TGR5) 对SARS-CoV-2引起的炎症的影响.
主要成果:
- *在严重的COVID-19病例中,观察到陈二氧化醇酸 (CDCA) 和糖二氧化醇酸 (GCDCA) 的显著降低.
- *在入院时的葡萄糖脱氧醇酸 (GCDCA) 水平与峰值炎症标志物相关.
- *CDCA,GCDCA和TGR5在实验室中证明了SARS-CoV-2引起的炎症的抑制,可能调节NOD类受体通路.
结论:
- * 降低CDCA和GCDCA水平与老年人严重的COVID-19有关.
- *CDCA和GCDCA显示出作为老年COVID-19患者疾病进展的预测生物标志物的潜力.
- *这些胆汁酸及其受体代表了针对严重的SARS-CoV-2感染的新型治疗策略的有希望的标.
更多相关视频
03:25Author Spotlight: Exploring Non-Pharmacological Therapies for Chronic Respiratory Diseases — Linking Intestinal Microbiome Insights to COPD Treatment
Published on: December 27, 2024
07:03Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss
Published on: July 19, 2024
相关概念视频
Chronic Pancreatitis II: Collaborative Care
Assessment:
Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation
Acute Pancreatitis II: Clinical Manifestations and Management
Atherosclerosis III: Management
COPD: Management Using Bronchodilators and Corticosteroids
Chronic Pancreatitis I: Introduction
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
